The Radiology of @entity174 in XXXX Related to Glucocorticoid Administration.

@entity1 @entity3604 @entity174 @entity170 @entity615 @entity79
UNASSIGNED: A number of unusual conditions cause decreased bone mass and density in @entity1 and these may be associated with @entity174 . However, a series of reports have more recently identified that @entity1 with @entity174 ( @entity174 ) much more often than had been suspected. The common denominator involved is glucocorticoid (GC) administration, although other factors such as disease activity come into play. This review will focus on the imaging findings in this form of secondary @entity170 . @entity174 in @entity1 have been found to correlate with @entity615 . At the same time, up to 2/3 of @entity1 with @entity174 in the GC-treated setting are asymptomatic, underscoring the importance of routine surveillance in at-risk @entity1 . Other predictors of prevalent and incident @entity174 include GC exposure (average daily and cumulative dose), declines in lumbar spine bone mineral density Z-scores and increases in body mass index Z-scores, as well as increases in disease activity scores. The imaging diagnosis of @entity3604 in @entity1 is made differently from that in adults because immature vertebral bodies continue to ossify during growth. Thus, it is not possible to assess the vertebral end plates or periphery until late, as enchondral ossification extends centripetally within the centrum. Diagnosis, therefore, is much more dependent upon changes in shape than on loss of structural integrity, which may have a more prominent diagnostic role in adults. However, @entity1 have a unique ability to model (a growth-dependent process) and thereby reshape previously fractured vertebral bodies. If the underlying disease is successfully treated and the @entity1 has sufficient residual growth potential, this means that, on one hand, treatment of the @entity79 may be of more limited duration, and, as a last recourse, the diagnosis may be apparent retrospectively.
